We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals

7.22 USD
-0.10
1.37%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
7.10
-0.12
1.66%
1 day
-1.37%
5 days
-5.37%
1 month
-9.07%
3 months
-25.26%
6 months
-17.39%
Year to date
-3.73%
1 year
2.7%
5 years
-42.01%
10 years
19.34%
 

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 435

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 48.1%
Neutral 51.9%
Negative 0%
Positive
MarketBeat
2 days ago
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
BioCryst Pharmaceuticals NASDAQ: BCRX expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies conference, while outlining plans to expand its hereditary angioedema portfolio and add rare-disease assets.
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
Neutral
GlobeNewsWire
9 days ago
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
Positive
Zacks Investment Research
12 days ago
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
Neutral
GlobeNewsWire
17 days ago
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m.
BioCryst to Present at Upcoming Investor Conferences
Neutral
Seeking Alpha
17 days ago
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Nick Wilder - Manager of Investor Relations Charles Gayer - CEO, President & Director Babar Ghias - CFO & Head of Corporate Development Sandeep Menon - Chief Research & Development Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Stacy Ku - TD Cowen, Research Division Jeremiah Lorentz - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the BioCryst Third Quarter 2026 Earnings Call.
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
Positive
Seeking Alpha
17 days ago
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
BioCryst Pharmaceuticals delivered Q3 2026 results ahead of expectations, maintaining 2026 guidance and highlighting Orladeyo's ongoing growth in a competitive HAE market. BCRX's valuation appears modest at ~3.5x forward P/S and ~11x forward P/E (excluding IPR&D), but future upside depends on pipeline execution, especially navenibart. Management pivots to external innovation, targeting >$1bn revenues by 2030 with Orladeyo, navenibart, and BCX17725, while royalty burdens are set to ease after 2029.
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
Positive
MarketBeat
18 days ago
BioCryst Pharmaceuticals Q3 Earnings Call Highlights
BioCryst Pharmaceuticals NASDAQ: BCRX reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.
BioCryst Pharmaceuticals Q3 Earnings Call Highlights
Positive
Zacks Investment Research
18 days ago
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago.
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
18 days ago
BioCryst Reports Third Quarter 2026 Financial Results
— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended September 30, 2026, and provided a business update.
BioCryst Reports Third Quarter 2026 Financial Results
Positive
Zacks Investment Research
23 days ago
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Price charts implemented using Lightweight Charts™